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A report on the 15th Lorne Cancer Conference, Lorne,
Australia, 13-16 February 2003.
The unifying theme of the 2003 Lorne cancer conference
was set by Nobel Laureate H. Robert Horvitz (Howard
Hughes Medical Institute and Massachusetts Institute of
Technology, Cambridge, USA) in the plenary address
describing his seminal work on the genetic control of pro-
grammed cell death in Caenorhabditis elegans. Apoptosis,
as he pointed out, is a major feature of normal development,
and disruption of this process results in a variety of human
disorders, including cancer. 
Cell death
The Nobel prize in physiology or medicine for 2002 was
awarded to Sydney Brenner (The Salk Institute, La Jolla,
USA), John Sulston (University of Cambridge, UK) and
Horvitz for their combined work in establishing C. elegans
as an experimental model organism and elucidating the
genetic pathway for programmed cell death. Robert Horvitz
extended the work of Brenner and Sulston by identifying the
central genes of the cell death (ced) pathway, including egl-1,
ced-3, ced-4 and ced-9. Loss-of-function mutations in egl-1,
ced-3 and ced-4 cause the 131 cells normally fated to die by
programmed cell death to survive in the adult hermaphro-
dite. Current work in the Horvitz lab centers on understand-
ing the signals between cells undergoing programmed cell
death and the cells that will engulf them. In a typically
simple yet powerful screen, Ced-3 hypomorphic mutant
worms have been made transgenic for a reporter construct
comprising green fluorescent protein (GFP) under the lin11
promoter (lin11::GFP), which marks ventral cord cells that
are fated to undergo programmed cell death. A combination
of mutagenesis and direct observation of GFP fluorescence
in live worms has led to the identification of a number of
mutations in known and novel genes that act in this
pathway. Two mutations disrupting the engulfment process
have been mapped to the dpl1 and MCD-1 genes.
Two major pathways control the caspase-dependent apopto-
sis of a cell, namely the extrinsic and intrinsic pathways. The
dogma in the field has suggested that initiation of the intrin-
sic pathway of apoptosis, which can be activated in response
to cytotoxic stress, such as DNA damage, requires permeabi-
lization of the mitochondria and subsequent formation of
the apoptosome, a protein complex made up of cytochrome
c, Apaf-1 and caspase-9. Given that cytochrome c release in
C. elegans and  Drosophila  is not required for apoptosis,
however, several groups have hypothesized that some apop-
totic pathways are independent of the mitochondria and the
apoptosome, and that the mitochrondria serve to amplify
but not to initiate the apoptotic caspase cascade.  
Yuri Lazebnik (Cold Spring Harbor Laboratory, USA)
described the use of the increasingly popular technology of
small interfering RNA (siRNA) to inhibit the production of
caspase-2. Using siRNA avoids the need to produce gene
knockouts and does not appear to produce the anti-viral
responses that are triggered by traditional antisense RNA
methods. Lazebnik and his coworkers have demonstrated
that inhibition of caspase-2 production using siRNA can
inhibit the translocation of the pro-apoptotic protein Bax
from the cytoplasm to the mitochondria following induction
of DNA damage with the drug etoposide. When translocated
to the mitochondria, Bax is involved in mitochondrial per-
meabilization and release of cytochrome c. Thus, caspase-2
activation precedes activation of the well-characterized
apoptosome cell-death machinery. One obvious implication
of this work is that a detailed study of caspase-2 activation in
human tumors may provide insight into the failure of apop-
tosis in vivo and lead to the discovery of new therapeutic
targets. Further evidence that caspase activation occurs
upstream of the mitochondria and that the apoptosomefunctions to amplify the caspase cascade was presented by
Vanessa Marsden (The Walter and Eliza Hall Institute of
Medical Research, Melbourne, Australia). In order to study
the requirement for Apaf-1 and caspase-9 in apoptosis, given
that deficiency of Apaf-1 and caspase-9 is lethal to mouse
embryos, Marsden and colleagues engineered mice in which
only the fetal liver cells are deficient in Apaf-1 and caspase-9
by transferring fetal liver cells deficient in these two proteins
into lethally irradiated wild-type hosts. They found that
apoptosis in lymphocytes in response to growth-factor with-
drawal and stress was largely unaffected by the loss of Apaf-1
and caspase-9. Similarly, apoptosis in embryonic fibroblasts
derived from embryos deficient in Apaf-1 and Caspase-9
appeared normal.
One of the most interesting observations made by Lazebnik
was that the field of apoptosis research is afflicted with an
overwhelming productivity. This is manifest in the more
than 10,000 articles that have been published yearly in this
field for the last few years. How, Lazebnik asks, are we to
assimilate and conceptualize all this information? To answer
his own question, he created an analogy of a broken transis-
tor radio. The functional properties of cellular signal trans-
duction can be likened to those of a transistor radio; both are
made up of many components, which function together to
receive, transduce and transmit specific signals. Could we as
biologists, fix a broken radio? Firstly, we might obtain
working examples of the radio and sooner or later find that
we could remove the back to see inside. We would study it
carefully and describe and categorize the size, morphology
and coloring of all the components. Next, some scientists
might begin a functional analysis by removing specific parts
or cutting their connections to other parts. Finally we could
arrive at a working model that might help us in diagnosing
the problem with the original radio. If the radio is not
working due to the lack of one component or a broken con-
nection, or perhaps a fused and discolored component, no
problem. We can replace the part and fix the radio. But what
if the radio does not work as a result of a number of small
changes in several tunable components not apparent in our
analysis? We need an electrical engineer with a circuit
diagram that describes the precise physical and functional
relationships between the components that make up the
transistor radio. Likewise, in order to understand cellular
signal transduction, perhaps we need to develop a formal
language to describe these relationships. 
Cytokine signaling 
In the Signaling and Cancer session, John O’Shea (National
Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health, Maryland, USA) described
finding patients with mutations in the cold autoinflammatory
syndrome 1 (CIAS1) gene; such mutations (of which 20 have
been reported) result in a spectrum of diseases, including
neonatal-onset multisystem inflammatory disease (NOMID,
also known as chronic infantile neurologic, cutaneous,
articular, or CINCA, syndrome). O’Shea found that patients
with  CIAS1 mutations resulting in NOMID syndrome
produce markedly elevated levels of the cytokines IL-3, IL-5,
IL-6, IL-1 and the IL-1 receptor antagonist, IL-1R. Interest-
ingly, mutations in CIAS1, which encodes the protein cry-
opyrin, a regulator of the transcription factor NF-B and the
processing of IL-1, were found only in approximately 50% of
the cases clinically identified as NOMID/CINCA syndrome.
O’Shea proposed that heterogeneity in the promoter or
intron regions of cryopyrin or cryopyrin homologs may
explain the spectrum of diseases in humans with this genetic
abnormality. Furthermore, he suggested that it may be
possible to alleviate some of the symptoms of this disease by
using drugs that block IL-1 signaling.
Dendritic cells are specialized antigen-presenting cells that
coordinate immune responses to bacterial and viral
pathogens. The development of dendritic cells is controlled
both by interactions with the stromal environment, includ-
ing T lymphocytes, and by cytokines, including those that
signal through receptors bearing the signal-transducing
 common chain, which is shared by receptors for IL-2, IL-4,
IL-7, IL-9 and IL-15. The Janus kinase Jak3 is an essential
signaling component immediately downstream of the
 common chain. Mice deficient in Jak3 show an impaired
response to IL-2, IL-4, IL-7 and IL-15. Morgan Wallace
(University of Massachusetts Medical School, Worcester,
USA) and collaborators have shown that Jak3-deficient mice
display a three-fold decrease in CD8+ splenic dendritic cells
whereas CD11+ splenic dendritic cell numbers were normal.
CD11+ cells are normally found in the marginal zone of the
spleen and are responsible for Th2 T-helper cell responses,
whereas CD8+ dendritic cells are found in T-cell areas of
the spleen and are probably the only dendritic cells capable
of cross-priming CD8+ T cells. To test whether the decrease
in CD8+ dendritic cells was a haematopoietic-specific
defect, bone-marrow chimeras were generated using Jak3-
deficient cells. The CD8+ dendritic cells isolated from these
chimeric mice showed a decrease in number and an increase
in the expression of the CD40, B7.1 and B7.2 activation
markers. Several possibilities have been suggested to
account for the observed alterations in dendritic cell popula-
tions: activated Jak3-deficient T cells may kill CD8+ den-
dritic cells or may provide inappropriate dendritic cell
maturation signals; disrupted splenic architecture may also
prevent normal maturation. An alternative hypothesis
revealed at the conference is that Jak3-deficient T cells
produce a three- to five-fold increase in levels of IL-10, pro-
viding a possible negative feedback signal for CD8+ den-
dritic cell development.
Cancer therapeutics
The conference included a number of notable presentations on
current research into cancer therapeutics. The applications
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Lam (University of California, Davis, USA) in a talk that
focused on anti-cancer drug development and cancer pro-
teomics. Combinatorial peptide chemistry is a blossoming
field that is increasingly being utilized for the identification
of cell-surface ligands and lymphocyte epitopes, and for
studies of peptides binding to the major histocompatability
complex (MHC), as well as vaccine development. The one-
bead one-compound library method was first described by
Lam in 1991: each 80-100 m bead expresses approximately
1013 copies of a unique peptide (of which there are up to 109
permutations). These peptide-coated beads are capable of
binding a desired target, such as an antibody, protein, cell-
surface receptor, tumor cell, virus or bacteria. Individual
beads bearing a particular peptide can be isolated and
sequenced by Edman degradation. This year, Lam described
a peptide library screen designed to identify specific peptides
that bind to tumor cells but not to normal cells. It is envis-
aged that these peptide agents could be used to target drugs
to tumor cells. Tumor-specific peptides prepared using
D-amino acids would be less likely to be rapidly degraded in
vivo or to induce immune responses and might therefore be
optimal as therapeutics. 
The conference was the occasion of the inaugural Ashley
Dunn oration. For the past decade, the Lorne cancer confer-
ence has been chaired by Ashley Dunn (Ludwig Institute for
Cancer Research, Melbourne, Australia). The success of the
conference during this time is undoubtedly a reflection of
the patience, commitment and grace under pressure that has
been a characteristic of Dunn’s tenure. The Ashley Dunn
oration acknowledges the contribution Dunn has made not
only to the Lorne Cancer Conference but to fostering
research excellence within the Australian research commu-
nity. Mary-Claire King (University of Washington, Seattle,
USA) delivered the inaugural Ashley Dunn oration on the
genetic analysis of breast and ovarian cancer in the past,
present and future. The first BRCA1 mutations in families
with inherited breast cancer were described by King and
others in the early 1990s. These researchers have continued
to define the spectrum of mutations present in the BRCA1
and BRCA2 genes in familial breast and ovarian cancer and
to search for other genes linked to these cancers. Recently,
King and co-workers observed that most of the BRCA1 muta-
tions cause truncation and loss of the carboxy-terminal
transactivation domain. They have also identified a number
of direct transcriptional targets of BRCA1, including the
genes encoding Myc and cyclin D1, which are frequently
overexpressed in breast tumors. In summary, the 15th
annual Lorne cancer conference confirmed that break-
throughs in understanding cancer can be achieved by using
the power of diverse yet complementary approaches.
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